Our human health awareness, increasing; The means of diagnosis and treatment of diseases are constantly being updated. But all these advances seem to defy disease. Take diabetes, for example. The incidence continues to rise, and about 50 percent of adults are pre-diabetic. People may sometimes look at their pets and wonder why their lot is less happy than that of their animals. So, the question is, do animals get diabetes? Does the phenomenon of diabetes in animals have any implications for us humans? Let’s combine history and recent scientific research to give you the answer.

Let’s start with a brief history of diabetes research. Diabetes mellitus, the term was used around 250 BC; In 400 BC, the Yellow Emperor’s Inner Canon recorded the quenching of thirst, because the symptoms of diabetics seemed to be caused by hunger and thirst. Diabetes, which appears in the medical literature, was first recorded in 1425. Then in 1776, it was discovered that the urine of people with diabetes might contain something like brown sugar. At the time when science was still in a state of chaos, the treatment of diabetes was also full of tricks. For example, patients have been advised to exercise on horseback to reduce urination.

Humanity’s understanding of diabetes, on the right track, is, in fact, related to animals. In 1889, researchers discovered the link between the pancreas and diabetes. They tested dogs. When the pancreas was taken out, dogs would show symptoms of diabetes. In 1910, scholars further established that diabetes was caused by a lack of insulin. At that time, a variety of diabetes diets were also emerging, mainly based on oats, milk, potatoes, and opium. In 1921 Dr Banting, using extracts from the pancreas of healthy dogs, reversed the symptoms of diabetes in dogs and found that acidifying alcohol inhibited the activity of trypsin. Using this method to treat extracts from the pancreas of animals, a higher purity of insulin was obtained. In January 1922, a 14-year-old boy was treated with insulin for the first time, and his blood sugar and urine sugar levels were successfully controlled. Dogs are credited with saving people with diabetes.

Scientists will not only use animals for disease research, but will also explore the relationship between animals and human diseases. In December 2020, researchers from Sweden and the UK published a paper in the British Medical Journal. The study looked at 130,000 pet dogs and 80,000 cats and their owners in Sweden. Health data on the pets and their owners were obtained during a six-year follow-up period.

The study found that there was an interaction between diabetes in dogs and their owners. If a dog has diabetes, the owner’s risk increases, and vice versa. Specifically, dogs with diabetes owners had a 28 percent increased risk of diabetes; If a dog has diabetes, the owner’s risk of developing the disease increases by 38%. Interestingly, there is no such interaction between pet cats and their owners. The researchers believe the phenomenon has to do with lifestyle. For example, if the owner is not active, he may be too lazy to walk the dog and become a homebody. After eating, he will lie down and stare at the dog, waiting for his blood sugar to rise. As for the lack of interaction between cats and their owners, it may be related to the cats’ habit of autonomous activity.

Whether an animal gets diabetes or not is also related to its own unique metabolic mechanism. In December 2020, a paper was published online in the Cell series Metabolism. The study found that swine cholic acid can improve glucose homeostasis through different signaling mechanisms, which is a key factor in the risk of developing diabetes in pigs. Bile acids, which assist in emulsifying and absorbing fats and cholesterol, are also important signaling molecules that regulate metabolism and synthesis. Pigs have high levels of pig cholic acid and its derivatives, which can deal with the elevated blood sugar caused by bile acid consumption and improve the secretion of glucagon-like peptides. As a result, researchers believe that if you can increase the levels of bile acid through the gut flora, you can control diabetes, which may become a way to fight the disease in the future.

Research on the correlation between animal and diabetes suggests that. The phenomenon of life is a complex and precise process, which is influenced by both the constitution and external factors. External factors, such as changes in lifestyle and diet, are relatively rapid processes, while internal mechanisms are relatively stable. In the past, people may not have enough to eat or not eat well, and do more physical work. Now, refined or processed food intake greatly increased, the body activity significantly reduced, the islet activity can not keep up with the change of rhythm, there will be insulin resistance and insulin level is quite insufficient, thereby causing the rise of blood sugar, leading to diabetes. We don’t have the strength of pig bile acid levels overnight, we have to control ourselves, or we get sick. This is destiny, and at the same time, it is a destiny that can be changed.

First, to meet patients

My visit on Saturday morning, I received a small patients, female, now eight years old, accompanied by my mother and I said, sick children already half a year, half a year ago due to colds, sore throat, cough, symptoms such as flow yellow stuff, at home to take medicine symptoms disappear, but a few days to go to school and repeatedly cough, sometimes a dry cough, sometimes with sputum, oral cephalosporins and stop coughing drugs has no obvious effect on its own. This cough is worse, especially at night and early in the morning. I want to seek the help of Chinese medicine treatment. I heard diffuse wheezing in both lungs on auscultation, prolonged expiratory phase, and no hyperemia in the pharynx. I found that the child’s face was pale with pale tongue and white fur, and there were no symptoms of wheezing, shortness of breath, or chest tiredness. The blood routine showed that white blood cells were 7.61*10^9/L, eosinophils were 7.70, and lymphocyte ratio was 39.3%. Combined with symptoms, cough variant asthma was diagnosed.

Second, the treatment process

Variable asthma is also called allergic cough, cough generally lasts more than four weeks, often in the night and (or) early morning attack or aggravation, mainly dry cough, no signs of infection in clinical, after a long time antibiotic treatment can be diagnosed as variable asthma, it is a kind of children’s asthma, the disease is mild, the prognosis is good. I use the method of integrated traditional Chinese and western medicine to give the treatment plan:

One oral loratadine syrup, once daily, anti-allergy therapy.

Inhalation of budesonide suspension and terbutaline sulfate aerosol, 1-2 times daily, is effective in relieving airway spasm.

3 reduce indoor pollution, maintain indoor good ventilation and certain insolation time, often sweep, vacuum, the ground does not spread carpet, purify cloth makes especially the toy that takes nap. Avoid contact with allergens, such as pollen, cockroaches, and fungi.

Four oral Suhuang cough capsule, three times a day, play the role of desensitization cough.

Five self-made Chinese medicine paste ointment daily Tiantu, Dazhui, Feishu, Pishu, Zusanli and other acupoints. Tonifying lung and invigorating qi, enhancing children’s immunity.

Three, matters needing attention

Because the child always cough, so the first thing to supplement moisture, parents should drink lots of water to the child, lest produce water shortages, but also pay attention to the child’s daily diet, don’t give her eat the food of acrimony stimulation, lest stimulate bronchial mucosa caused severe cough, if parents smoke, must pay attention to go outside to smoke, smoke spread a loose it back again after contact with children, The smell of smoke can also irritate the airways and make coughing worse. Daily take the children out for a walk to exercise, but now there are catkins outside the season, pay attention to children wearing masks, wear the right amount of clothes, do not wear more or less, this is not conducive to the recovery and treatment of the disease.

Four, therapeutic effect

After treatment for a week, the child’s cough frequency is reduced. At night and occasionally in the morning, the child can have a good sleep and the complexion is improved. After treatment for half a month, there was no cough at night or in the morning, but only after activity in the daytime. The cough was dry, no phlegm, no other uncomfortable symptoms, increased appetite and adequate sleep. After a month of treatment, all the symptoms disappeared and the mother told me that she could no longer hear her cough.

5. Insight of doctors

In this case, the child is coughing for half a year parents didn’t get to see a doctor, actually already very delayed treatment, may not let the child have asthma, but is because drag not to treat the disease, finally caused asthma, many children trouble started are caused by slight illness, parents feel just caught a cold not good, no seriously on the heart, As a result, after a period of time, it becomes a serious illness, not only delaying treatment, but also affecting the extent of the disease. Parents are the best teachers, the children when their parents don’t care about the child’s disease at an early age, it is easy to cause the child grow up to also have the same psychological, feel myself is a small problem, need not special care, in the long term the problem could be intensified eventually become a big problem is incurable, body uncomfortable, so it is medical treatment in time, don’t procrastination disease, Not only for children, but also for our adults. Most of the time, adults feel that what the disease is gone, but some diseases are not so simple as imagined. We must come to the hospital for treatment in order to get the best recovery.

As the saying goes: “an apple a day keeps the doctor away from me.” Eating apples often has many health benefits《 Exceed the standard or obesity incidence rate of people who eat apples every day can help reduce inflammation in the body and reduce the incidence of diseases such as cardiovascular diseases, which are closely related to inflammation, a new Canadian study published in the American Journal of clinical nutrition.
Dr. Lindsay Robinson, a researcher in the Department of human health and Nutrition Sciences at the University of Guelph in Canada, and his team of participants conducted a six week comparative study. The average age of participants was 45.4 years, and the average body mass index (BMI) was 33.4. The researchers randomly divided the participants into two groups. For the first two weeks, all participants avoided foods and beverages rich in polyphenols and dietary fiber. After that, in addition to the normal diet, the participants in group a ate three Gala apples a day (the edible part was about 200 grams), while the participants in group B did not eat apples. The intake of polyphenols and dietary fiber was limited for 6 weeks. Fasting blood samples were collected before and after 6 weeks to analyze the plasma biomarkers. The results showed that the levels of inflammatory markers such as fasting C-reactive protein, interleukin-6 (IL-6) and lipopolysaccharide binding protein in group A were 17%, 12.4% and 20.7% lower than those in group B, respectively. In addition, the levels of IL-6 and IL-17 secreted by PBMC decreased by 28.3% and 11%, respectively, and the plasma total antioxidant capacity increased by 9.6%. However, the new results also show that eating apples has no effect on weight loss, and has no effect on cardiovascular risk indicators such as blood glucose, insulin, blood pressure and blood lipids.
Dr. Robinson said the new findings suggest that eating apples every day is an effective way to reduce the chronic inflammation associated with obesity

With accelerated development in the field of early screening, the companies products, industry development, in the direction of the mature specification in education at the same time, focus on clinical research and market in the future how to solve the problem of multi-channel, pay problem, make cancer early screening, really meet the needs of clinical pain points and patients become cancer early sieve enterprise need to think about and layout problem.

“Partnering can bring 1+1.
All parties can make full use of their strengths to provide comprehensive services of ‘platform, technology, medical care and security’ for patients and their families, “Zhou Jun, CEO of Herui Genomics, told Caijing.
In the past year, Herui Genomics has been exploring cooperation with insurance, Internet companies, tumor imaging companies and many other role enterprises.
“This collaboration and ali health, is based on our people to disease classification and positioning for early screening target population, first of all on liver cancer early screening products out of the first step, but will also continue to cooperation, will explore more likely, from medicines to insurance, even based on ali health data for clinical exploration and development technology, and more cooperation in the future.”

“Only by forming a closed loop can we call it a complete early screening program.”

Announced a few days ago, ali health officially launched “slow disease protection scheme”, introduced millions of health care service “hepatitis b protect”, according to ali’s health, according to demand of hepatitis b patients with buy medicine and protection, can choose many hepatitis b daily medicine, if the insured person to cirrhosis of the liver, unfortunately by the applicant for liver cancer early screening, even after the diagnosis of liver cancer,
The insured will also receive expert consultation services provided by Ali Health and reimbursement of medical expenses for liver cancer provided by Zhongan Insurance.

The whole project in the middle of the ring is in a high-risk population screening for link, this part of the crowd in turn cancer risk compared with the general significantly increased in patients with liver disease, “this and our people to disease classification and early screening the positioning of the target population is the same, we need to identify high-risk in slow disease, extremely high risk people”,
In this project, by providing the early screening product of liver cancer, Lathning, HerueGenomics set up an online and offline integrated health service mode, providing solutions including prevention, screening, treatment and rehabilitation for people at high risk of liver cancer. Together, HerueGenomics has opened a closed loop of “medical treatment + medicine + testing + insurance”.

“This collaboration is the first step based on HCC early screening products, but the collaboration will continue, and more possibilities will be explored, ranging from drugs to insurance, and even clinical exploration and development based on Ali Health data technology, as well as cooperation on more products in the future,” Zhou told Caijing.

In the field of early screening and diagnosis of tumors, Herugenomics has launched a series of clinical research projects on early screening and early diagnosis of tumors, including liver cancer, lung cancer and other high-risk tumors in China. The clinical grade liver cancer early screening product Lesning has been launched in August 2020.
With the launch of products and the rapid development of the industry, while focusing on clinical research and market education, cancer early screening companies need to think and layout about how to solve the problem of multi-channel and multi-payment in the future, so that cancer early screening enterprises can truly realize the implementation of clinical pain points and patients’ needs.

In this project, the two sides will provide users with multi-level health security system and compensation system, “lai si ning” as part of an insurance premium services, and in the past few months, and gene is active cooperation and more insurance companies to explore, in March 2021, and genes and taikang online, anhua agricultural insurance also reached a cooperation, respectively.

“Medical insurance is the ideal, while commercial insurance is the reality,” said Zhou Jun frankly. Public hospitals in China are the dominant ones, and patients in hospitals are one of the main business models for early screening products. Cancer early screening still needs to be paid by oneself.
The second is to adapt to the clinical environment in China. What are the needs of the patients? The examination alone cannot solve the problem of payment or diagnosis and treatment, so it cannot be called a complete early screening program.”

In his view, building a Chinese program for early cancer screening and prevention requires the integration of all aspects, from commercial to clinical, from technology to industry.
“In the future, the company will continue to deepen the depth and breadth of cooperation with partners, expand the layout of cancer early screening product line, inject new momentum into the research and development of high incidence and high-risk cancer early screening in China, and work with ecological partners to realize the mission of ‘early diagnosis and early treatment for all tumors’.”

“Clinical grade early screening products depend on the data”

According to ali, health, vice President, noting, “based on the health of the whole scene ali medical service capacity, and high specificity of genome and gene detection technology and large sample clinical research, the further cooperation is the comprehensive exploration on the disease care, and will use science and technology innovation, around more diseases to design a new model of health management.”
Zhou Jun also revealed that Ali Health had done a lot of “back research” before choosing Hexigen, and had made an understanding of the technical path and clinical data of the product.

A clinical-grade early screening product still depends on the data.
In 2020, Hereogen announced the roadmap for early screening and early diagnosis of multiple tumor species:
Within three to five years, Herui Genomics will deliver research results on early screening and early diagnosis of 5 to 8 types of high-risk and high-incidence tumors in China, and carry out industrial implementation. Lesning will be launched in August 2020 for the screening of liver cancer in high-risk groups, which is 6-12 months earlier than the traditional method for the early warning of liver cancer.
The related achievements of HIFI technology have also been published in the international authoritative journal Cell Research (IF=20.5), which has been recognized by international authorities.

On June 22, the Chinese Journal of Liver Diseases officially published the first expert consensus on early screening strategies for liver cancer in China, which was led by the national multi-center prospective screening program for extremely early warning of liver cancer (PRECAR).
Herui gene cfDNA whole genome sequencing technology for early screening of liver cancer is incorporated into the “pyramid” model for early screening of liver cancer. Through the model of preliminary screening, fine screening and early diagnosis, the risk groups are enriched and concentrated layer by layer, and the detection efficiency of early liver cancer is finally improved.
The Consensus showed that the HIFI scoring model based on cfDNA whole genome sequencing had a stable performance, with a sensitivity of 95.42% and specificity of 97.91% to distinguish between HCC and non-HCC.

“A product can’t solve a clinical problem and will eventually degenerate into a consumer product,” Zhou Jun told Caijing.com. “China’s clinical environment is centered on clinicians, and doctors’ opinions and opinions are very important to the implementation of early screening products in the whole society.
At the same time, the approval of clinicians is not only an endorsement, we want to provide early screening program, the other end of the cancer diagnosis and treatment loop occurs in the clinic, the screening results must be accepted by the clinic, the clinical program can be adjusted accordingly, if the clinic is not recognized, this value will be greatly reduced.
Based on these two factors, we think it’s time to put resources into the clinic.”

In April of this year, the Precar program announced new progress and will launch the Ⅱ phase III clinical application extensibility study, which extends from early screening to the management of the entire course of HCC.

Why the Ⅱ phase III trial?
“One is to give people a better understanding of the performance and clinical use of our products, and the other is to help doctors deepen their understanding of clinical testing,” said Zhou Jun.

About how to understand to the whole course of the management of liver cancer, he explains the financial network, “the first is about some malignant nodules, because now we say that the liver is above there are a lot of nodules, cirrhosis of the liver itself has nodules, how to determine the clinical doctors are interested in, which is originated in the us with clinical doctors to do some tests, and see if I can do the judgement of nodules.
The clinician also mentioned that since early screening can be done to detect recurrence, “the underlying technology is similar, we will make some adjustments, and we will judge whether it can adapt to the actual clinical results, and finally illustrate with data.”